Modeling the Cost-Effectiveness of Novel Direct Acting Antiviral (DAA) Treatments In Patients Co-Infected with Hepatitis C Virus (Hcv) and Human Immunodeficiency Virus (HIV)
Abstract
Authors
P. McEwan T. Ward S. Webster A. Kalsekar M. Brenner Y. Yuan